{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:43:56Z","timestamp":1785336236295,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Padjadjaran"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Preeclampsia (PE) is a hypertensive disorder in pregnancy involving multiple organ systems, primarily due to impaired placental development during the first trimester. Reduced Placenta Growth Factor (PlGF) and elevated Glycosylated Fibronectin (GlyFn) levels reflect these pathological changes. Combining these biomarkers into a ratio may enhance PE prediction in high-risk pregnancies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the GlyFn\/PlGF ratio measured at 20\u201328 weeks of gestation as a predictor of preeclampsia in high-risk pregnancies across four hospitals in West Java, Indonesia, from April\u2013October 2024.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective cohort study involved 54 high-risk pregnant women. The GlyFn\/PlGF ratio was analyzed at 20\u201328 weeks to assess predictive accuracy for PE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Significant differences were noted between PE and non-PE groups in pre-pregnancy weight (65.54\u2009\u00b1\u200912.69 vs. 58.53\u2009\u00b1\u20097.85\u00a0kg), BMI (45.52\u2009\u00b1\u200953.73 vs. 19.84\u2009\u00b1\u20092.97), and systolic blood pressure (153.50\u2009\u00b1\u200919.42 vs. 100.80\u2009\u00b1\u200915.38 mmHg) (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Risk factors such as prior PE (<jats:italic>P<\/jats:italic>\u2009=\u20090.01), diabetes mellitus (<jats:italic>P<\/jats:italic>\u2009=\u20090.03), and gestational hypertension (<jats:italic>P<\/jats:italic>\u2009=\u20090.02) were more frequent in the PE group. A GlyFn cutoff of 34.31 ng\/mL showed a 2.5-fold increased PE risk (sensitivity: 83.33%, specificity: 66.67%, AUC: 0.8071). A PlGF cutoff of 26.72 pg\/mL was associated with a 6.8-fold increased risk (sensitivity: 72.22%, specificity: 97.22%, AUC: 0.9147). The GlyFn\/PlGF ratio cutoff of 1.288 indicated a 28-fold higher PE risk (sensitivity: 77.78%, specificity: 97.37%, AUC: 0.9244).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The GlyFn\/PlGF ratio outperforms individual biomarkers in predicting preeclampsia in high-risk pregnancies, offering a valuable tool for early risk identification and timely intervention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12884-025-07853-0","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:22:00Z","timestamp":1752776520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive value of Glycosylated Fibronectin (GlyFn)\/Placenta Growth Factor (PlGF) ratio for high-risk pregnancies: a cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Wahyudi","family":"Wirawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Rifayani","family":"Krisnadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Deborah","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annisa Dewi","family":"Nugrahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"3","key":"7853_CR1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.15296\/ijwhr.2021.30","volume":"9","author":"A Pribadi","year":"2021","unstructured":"Pribadi A. Zero mother mortality preeclampsia program: opportunity for a rapid acceleration in the decline of maternal mortality rate in Indonesia. Int J Womens Health Reprod Sci. 2021;9(3):160\u20133.","journal-title":"Int J Womens Health Reprod Sci"},{"issue":"11","key":"7853_CR2","first-page":"47","volume":"9","author":"AY Pramatirta","year":"2016","unstructured":"Pramatirta AY, Bremmy L, Fauziah PN, Anwar AD, Krisnadi SR. Effects of low dose aspirin on caspase 3, TNF-\u03b1 and apoptotic index levels in preclampsia maternal Serum-Induced placental trophoblast cell line in vitro. Int J PharmTech Res. 2016;9(11):47\u201353.","journal-title":"Int J PharmTech Res"},{"issue":"2","key":"7853_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/FM9.0000000000000097","volume":"3","author":"D Sroka","year":"2021","unstructured":"Sroka D, Verlohren S. Short term prediction of preeclampsia. Maternal-Fetal Medicine. 2021;3(2):107\u201315.","journal-title":"Maternal-Fetal Medicine"},{"key":"7853_CR4","doi-asserted-by":"crossref","unstructured":"Hypertension in Pregnancy: Executive Summary. Obstetrics & Gynecology. 2013;122(5):1122-31.","DOI":"10.1097\/01.AOG.0000437382.03963.88"},{"key":"7853_CR5","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","volume":"135","author":"Gestational hypertension and preeclampsia","year":"2020","unstructured":"Gestational hypertension and preeclampsia. ACOG practice bulletin 222. American college of obstetricians and gynecologists. Obstet Gynecol. 2020;135:e237\u201360.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"7853_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/FM9.0000000000000088","volume":"3","author":"RA Abbas","year":"2021","unstructured":"Abbas RA, Ghulmiyyah L, Hobeika E, Usta IM, Mirza F, Nassar AH. Preeclampsia: a review of early predictors. Maternal-Fetal Medicine. 2021;3(3):197\u2013202.","journal-title":"Maternal-Fetal Medicine"},{"issue":"19","key":"7853_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMra2109523","volume":"386","author":"LA Magee","year":"2022","unstructured":"Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. N Engl J Med. 2022;386(19):1817\u201332.","journal-title":"N Engl J Med"},{"key":"7853_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s13104-015-1506-0","volume":"8","author":"JI Gurnadi","year":"2015","unstructured":"Gurnadi JI, Mose J, Handono B, Satari MH, Anwar AD, Fauziah PN, Yogi Pramatirta A, Rihibiha DD. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1\/PlGF ratio in severe preeclampsia and normal pregnancy. BMC Res Notes. 2015;8:534.","journal-title":"BMC Res Notes"},{"issue":"12","key":"7853_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/jhh.2017.61","volume":"31","author":"K Chau","year":"2017","unstructured":"Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017;31(12):782\u20136.","journal-title":"J Hum Hypertens"},{"issue":"4","key":"7853_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00404-020-05670-8","volume":"302","author":"J Alanen","year":"2020","unstructured":"Alanen J, Appelblom H, Korpimaki T, Kouru H, Sairanen M, Gissler M, et al. Glycosylated fibronectin as a first trimester marker for gestational diabetes. Arch Gynecol Obstet. 2020;302(4):853\u201360.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"7853_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/uog.27451","volume":"62","author":"S Moungmaithong","year":"2023","unstructured":"Moungmaithong S, Wang X, Lau CSL, Tse AWT, Lee NMW, Leung HHY, et al. Glycosylated fibronectin improves first-trimester prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2023;62(4):512\u201321.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"5","key":"7853_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23740","volume":"35","author":"J Wang","year":"2021","unstructured":"Wang J, Hu H, Liu X, Zhao S, Zheng Y, Jia Z, et al. Predictive values of various serum biomarkers in women with suspected preeclampsia: a prospective study. J Clin Lab Anal. 2021;35(5): e23740.","journal-title":"J Clin Lab Anal"},{"issue":"7","key":"7853_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","volume":"125","author":"S Rana","year":"2012","unstructured":"Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125(7):911\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.054361","journal-title":"Circulation"},{"issue":"1","key":"7853_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/10641955.2019.1660609","volume":"39","author":"G Guti\u00e9rrez-Guti\u00e9rrez","year":"2020","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez G, Galindo A, Puertas A, et al. Glycosylated fibronectin as a biomarker for the prediction of preeclampsia. Hypertens Pregnancy. 2020;39(1):62\u201370. https:\/\/doi.org\/10.1080\/10641955.2019.1660609.","journal-title":"Hypertens Pregnancy"},{"key":"7853_CR15","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/j.ajog.2014.07.052","volume":"212","author":"J Rasanen","year":"2015","unstructured":"Rasanen J, Quinn MJ, Laurie A, Bean E, Roberts CT Jr, Nagalla SR, et al. Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia. Am J Obstet Gynecol. 2015;212:e821\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"7853_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12884-020-2809-2","volume":"20","author":"EA Huhn","year":"2020","unstructured":"Huhn EA, Hoffmann I, Martinez De Tejada B, Lange S, Sage KM, Roberts CT, et al. Maternal serum glycosylated fibronectin as a short-term predictor of preeclampsia: a prospective cohort study. BMC Pregnancy Childbirth. 2020;20(1):128.","journal-title":"BMC Pregnancy Childbirth"},{"key":"7853_CR17","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/1471-0528.16323","volume":"127","author":"SR Nagalla","year":"2020","unstructured":"Nagalla SR, Janaki V, Vijayalakshmi AR, Chayadevi K, Pratibha D, Rao PV, et al. Glycosylated fibronectin point-of-care test for diagnosis of pre-eclampsia in a low-resource setting: a prospective Southeast Asian population study. BJOG. 2020;127:1687\u201394.","journal-title":"BJOG"},{"key":"7853_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091198","author":"VL Bilano","year":"2014","unstructured":"Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia\/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS One. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0091198.","journal-title":"PLoS One"},{"issue":"3","key":"7853_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ajog.2023.03.032","volume":"229","author":"P Chaemsaithong","year":"2023","unstructured":"Chaemsaithong P, et al. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023;229(3):222\u201347.","journal-title":"Am J Obstet Gynecol"},{"issue":"87","key":"7853_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20870","volume":"20","author":"GK Frampton","year":"2016","unstructured":"Frampton GK, Jones J, Rose M, Payne L. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess. 2016;20(87):1\u2013160.","journal-title":"Health Technol Assess"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-07853-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-025-07853-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-025-07853-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:10:33Z","timestamp":1757250633000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-025-07853-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7853"],"URL":"https:\/\/doi.org\/10.1186\/s12884-025-07853-0","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations after obtaining approval and recommendations from the Ethics Committee Review Board of Hasan Sadikin General Hospital\u2013 Faculty of Medicine, Universitas Padjadjaran with reference number DP.04.03\/D.XIV.6.5\/125\/2024, in compliance with the Helsinki Declaration. Written informed consent were obtained from patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"770"}}